Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : AnovoRx | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
Details : Tiratricol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Allan-Herndon-Dudley syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : AnovoRx | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Premier Research Group | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tiratricol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Allan-Herndon-Dudley syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Premier Research Group | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Solasia Pharma KK
Deal Size : Inapplicable
Deal Type : Inapplicable
Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer
Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2019
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Solasia Pharma KK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Solasia Pharma KK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2018
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Solasia Pharma KK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects
Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chemotherapy-induced Peripheral Nervous System Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 13, 2018
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : University of Edinburgh | NHS Lothian
Deal Size : Inapplicable
Deal Type : Inapplicable
PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2017
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : University of Edinburgh | NHS Lothian
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Deal Size : Inapplicable
Deal Type : Inapplicable
Triac Trial II in MCT8 Deficiency Patients
Details : Triac is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Allan-Herndon-Dudley syndrome.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 24, 2015
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pharma Consulting Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calmangafodipir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2012
Lead Product(s) : Mangafodipir Trisodium
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pharma Consulting Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
